Teva presents positive efficacy and safety data of AJOVY® (fremanezumab) for the prevention of episodic migraine in children and adolescents from Phase 3 SPACE trial 4 December 2024: Teva Pharmaceutical Industries Ltd presented positive data from its Phase 3 SPACE study evaluating the efficacy and safety of AJOVY® (fremanezumab) for the prevention of episodic migraine…
Category: Headache
Triptans effective for acute migraine sufferers
Study suggests Triptans are the most effective medicine for adults who experience acute migraines Findings of a study, in which researchers looked at 137 controlled trials that tested oral drugs commonly used to treat migraines, have been published in The British Medical Journal. The trials involved a total of 89,445 patients who were given one of 17…
Ubrelvy can prevent migraines when used early
AbbVie’s Ubrelvy (ubrogepant) — which is approved to treat migraines – can also help to prevent them when used before the onset of headache pain, according to a recent study from Neurology journal. The phase 3 PRODROME Trial suggests that Ubrelvy was 73% more effective in preventing a migraine attack than a placebo. In the…
Data challenges migraine treatment pauses
New AJOVY® (fremanezumab) migraine prevention data presented at the EAN July 1, 2024: Teva Pharmaceutical Industries Ltd announced new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some…
Non-pharmacological migraine treatment
Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA Feb. 20, 2024: Theranica, a prescribed digital therapeutics company specialising in neuromodulation devices for migraine and other idiopathic pain conditions, announced the inclusion of its Nerivio Remote Electrical Neuromodulation (REN) wearable, for use in the acute and preventive…
Preventing migraine with CGRP
PRODROME trial shows CGRP in migraine prodrome can stop headache and reduce severity 11 December, 2023: Research shows that taking a specific class of migraine medication during the prodromal phase reduces the development and severity of the subsequent headache. In the randomised, placebo-controlled PRODROME trial, treatment with ubrogepant (Ubrelvy) 100 mg, one of the new CGRP…
Migraine and obesity
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity 6th December, 2023: Teva Pharmaceuticals has announced that a post hoc analysis [iv] of two Phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY®…
Ubrelvy for migraine: positive phase III data
AbbVie recently announced its publication in The Lancet showing that administration of Ubrelvy (ubrogepant) during the prodrome stage of a migraine can reduce the likelihood of a migraine attack developing. Ubrelvy is the first and only acute migraine treatment that has demonstrated Phase III data in the prodrome stage. Christie Wong, Pharma Analyst at GlobalData,…
Are CGRP medications effective against migraine in men?
Via Medscape: Most patients with migraine are women. This female predominance is reflected in the clinic and in clinical trials, where ~85% are women. A pharmacologist and a neurologist from the United States argue that the efficacy of calcitonin gene-related peptide (CGRP)-based migraine therapies has been proven in women but not in men, and that men should be informed…
